Table 3 List of potential compounds for repurposing with anti-Zika activity, extracted from [19, 83]
From: Zika vaccines and therapeutics: landscape analysis and challenges ahead
Drug group | Drug name | Description |
|---|---|---|
Nucleoside analogs | Sofosbuvir, MK-608 | • Inhibit Zika virus (ZIKV) replication in cellular assays • Efficacious in animal models |
2CMC, Ribavirin, Favipiravir, T1105 | • Showed antiviral activity in cell culture | |
BCX4430, GS5734 | • Reduced mortality in ZIKV-infected mice • Currently in phase I and II clinical trials | |
Peptidomimetic agents | CN-716 | • Inhibit ZIKV protease in vitro, but only weakly inhibit viral replication • Due to safety reasons, may not translate as therapeutic option for pregnant women, but could be applied to other infected individuals |
Adenosine analog | NITD008 | • Showed potent anti-ZIKV activity • Could serve as a reference inhibitor for future drug screen and discovery |
Cyclin-dependent kinase inhibitor | PHA-690509 | • Showed inhibition of ZIKV replication of all three strains |
Antimalaria | Chloroquine | • Reduces virus production, the number of infected cells, and cell death promoted by ZIKV infection without any cytotoxic effect • Promising candidate for ZIKV clinical trials • Can be safely administered to pregnant women since it is clinically approved |
Anthelmintic | Bithionol | • Propagate by activating host caspases and inducing programmed cell death |
Epigallocatechin gallate |  | • Natural compound found in food items, particularly green tea • It inhibits ZIKV entry into host cell |
Interferon-inducible transmembrane proteins |  | • Inhibit the replication of a number of pathogenic viruses |